EUVIMEDEUVIMED entdecken
Crossref

Cumulative Equivalent Dose in 2 Gy Fractions (EQD2) to the Target and Organs at Risk Following External Beam Radiotherapy and CT-Guided High-Dose-Rate Intracavitary Brachytherapy in Locally Advanced Carcinoma Cervix: A Prospective Dosimetric Study

Vipul Mehta, Manish Kumar Chaturvedi, Abhay Jain, Rohitashwa Dana, Shivani Gupta

International Journal of Pharmaceutical Quality Assurance · 30.06.2026 · 17 (06)

DOI: 10.25258/ijpqa.17.6.45 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.06.2026. Verfasst von Vipul Mehta und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Locally advanced carcinoma cervix is commonly treated with external beam radiotherapy (EBRT) followed by high-dose-rate (HDR) intracavitary brachytherapy. Accurate estimation of cumulative radiation dose to the target and organs at risk is essential for optimizing tumour control while minimizing treatment-related toxicity.

Aim

This study aimed to evaluate the cumulative equivalent dose in 2 Gy fractions (EQD2) delivered to the target volume and organs at risk following EBRT and CT-guided HDR intracavitary brachytherapy in patients with locally advanced carcinoma cervix. Materials and Methods: This prospective observational dosimetric study included 22 patients with histopathologically confirmed locally advanced carcinoma cervix, FIGO stage IIB–IIIB. All patients received EBRT to a dose of 50 Gy in 25 fractions, followed by CT-guided HDR intracavitary brachytherapy of 7 Gy per fraction for three fractions. Dose–volume histogram parameters were recorded for the target volume, bladder and rectum. Cumulative EQD2 was calculated using the linear–quadratic model, with an α/β ratio of 10 Gy for the target and 3 Gy for organs at risk.

Results

The mean age of patients was 59.1 ± 7.7 years. Stage IIB disease was present in 59.1% of patients, while 40.9% had stage IIIB disease. The mean target D90 was 8.05 ± 1.59 Gy per brachytherapy fraction. The mean cumulative EQD2 to the target was 86.90 ± 10.11 Gy. The mean cumulative EQD2 to the bladder and rectum, calculated using D2cc, was 93.93 ± 13.41 Gy and 78.39 ± 9.14 Gy, respectively.

Conclusion

CT-guided HDR intracavitary brachytherapy combined with EBRT provided satisfactory target dose coverage and enabled accurate volumetric assessment of organs at risk in patients with locally advanced carcinoma cervix. Cumulative EQD2-based evaluation is a useful method for biologically meaningful dose assessment and treatment optimization. Larger multicentric studies with long-term follow-up are required to correlate cumulative EQD2 with clinical outcomes and late radiation toxicity.

Zitieren

APA

Mehta, V., Chaturvedi, M. K., Jain, A., Dana, R., & Gupta, S. (2026). Cumulative Equivalent Dose in 2 Gy Fractions (EQD2) to the Target and Organs at Risk Following External Beam Radiotherapy and CT-Guided High-Dose-Rate Intracavitary Brachytherapy in Locally Advanced Carcinoma Cervix: A Prospective Dosimetric Study. International Journal of Pharmaceutical Quality Assurance, 17(06). https://doi.org/10.25258/ijpqa.17.6.45

Vancouver

Mehta V, Chaturvedi MK, Jain A, Dana R, Gupta S. Cumulative Equivalent Dose in 2 Gy Fractions (EQD2) to the Target and Organs at Risk Following External Beam Radiotherapy and CT-Guided High-Dose-Rate Intracavitary Brachytherapy in Locally Advanced Carcinoma Cervix: A Prospective Dosimetric Study. International Journal of Pharmaceutical Quality Assurance. 2026;17(06). doi:10.25258/ijpqa.17.6.45

BibTeX
@article{Mehta2026,
  author = {Mehta, Vipul and Chaturvedi, Manish Kumar and Jain, Abhay and Dana, Rohitashwa and Gupta, Shivani},
  title = {Cumulative Equivalent Dose in 2 Gy Fractions (EQD2) to the Target and Organs at Risk Following External Beam Radiotherapy and CT-Guided High-Dose-Rate Intracavitary Brachytherapy in Locally Advanced Carcinoma Cervix: A Prospective Dosimetric Study},
  journal = {International Journal of Pharmaceutical Quality Assurance},
  year = {2026},
  volume = {17},
  number = {06},
  doi = {10.25258/ijpqa.17.6.45}
}
Kostenlos starten →